JIKEI HEART STUDY PDF
The addition of valsartan to optimized therapy in a cohort of Japanese patients with coronary heart disease and hypertension provides. Description: RETRACTION: The editors of the European Heart Journal have retracted the article reporting data/results of the Jikei Heart Study. The Lancet has formally retracted the Jikei Heart Study paper, originally published in The retraction had been widely anticipated for more.
|Published (Last):||15 December 2004|
|PDF File Size:||3.72 Mb|
|ePub File Size:||2.84 Mb|
|Price:||Free* [*Free Regsitration Required]|
It is therefore important to verify that the results of these studies are also valid for Japanese patients. An investigating committee headed by Professor Hashimoto from Jikei University was established. We wrote again on June 4 and June 19 asking when the investigation might be completed. The primary endpoint will be the onset of any studdy event.
Lancet retracts Jikei Heart Study of valsartan following investigation
The follow-up period will be three years. Another outrageous and potentiall quite dangerous violoation of medical, scientific, and human ethics by Big Pharma trying to sell their products.
Dr Azam also told us: Eur Heart J ; Several recent clinical trials have demonstrated that angiotensin II receptor blockers ARBs have cardiovascular as well as renal protective effects.
The Lancet deserves a tip of our hat for such a detailed note. Concerns about the Jikei Heart Study. We wrote again on July 31 after we were made aware that a press conference had been held. Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: Secondary endpoints will include death from any cause, changes hearh left ventricular size and function, renal function, changes in neuro-hormonal levels and quality-of-life assessments.
Learn how your comment data is processed. When the Jikei Heart Study was first published, Staessen and Richart 2 congratulated the investigators on their report. This site uses Akismet to reduce spam.
Our attempts to obtain a response from Mr Shirahashi were hindered by his recent retirement from Novartis, but the Global Head of Medical Affairs, Dr Usman Azam, did share with The Lancet that Mr Shirahashi had been employed by Novartis throughout the period of the trial and its publication. Sub-studies will explore the effect in patients with diabetes mellitus, hyperlipidemia and the effects of combination of drugs.
Improved prognosis would confirm the role of angiotensin II receptor blockers in the treatment of the cardiovascular disease in Japanese patients. Follow Follow this blog Get every new post delivered right to your inbox. Sorry, your blog cannot share posts by email. The report identifies concern over the reliability of the blood pressure data: Matsubara is not an author on the Jikei study.
Although we were initially satisfied with their response, in we published a letter from Dr Yui reporting further concerns. Valsartan in a Japanese population with hypertension and other cardiovascular disease Jikei Heart Study: I hope many more journals will take the same detailed approach.
Accumulated sales of Diovan in Japan reaches 12 billion dollars US! Leave a Reply Cancel reply Your email address will not be published.
Papers on potential cancer drugs retracted for image manipulation. We became aware of this development on April 29,and on May 2 we wrote to Jikei University asking for details of the investigation and requesting that we be kept informed.
He held the position until Larry Husten, at Cardiobrief, has been following the story in detail, and notes that the saga began with questions about papers by Hiroaki Matsubarawho now has eight retractions.
If the CNS journals did the right thing, we would have seen several more retractions recently McGill etc. Of course, The Lancet has been burned before Wakefield… and this is a clinical trial not basic science — hence sanity has prevailed.
The government is now investigating how to recover monies from Novaritis, a company obtaines so much moneny based on false and fabrictated data. Your email address will not be published.
Lancet retracts Jikei Heart Study of valsartan following investigation – Retraction Watch
Taken together, these findings indicate that there is now sufficient doubt as to the integrity of the Jikei Heart Study and the obfuscation over affiliation of the study statistician for The Lancet formally to retract the paper from the scientific record. Given this finding, we now wish to retract the Jikei Heart Study on the grounds that we no longer have confidence in the published results.
Too much skin in the game, as duplications force retraction of psoriasis paper.
But we soon became aware that there was concern in Japan about the trial. The JIKEI HEART Study has been designed to investigate whether concomitant treatment with valsartan, an angiotensin II receptor blocker, in addition to conventional treatment, will improve the prognosis of Japanese patients with cardiovascular diseases hypertension, ischemic heart disease, congestive heart failure.
The report also comments on the affiliation of the person entrusted with the statistical analysis, Nobuo Shirahashi.
This is outragenous given all those incomes come from healthinsurance and copay form patients.